Correlation of renal function with intra-patient variability of tacrolimus concentration among recipients of renal transplants: a 10-year study.

Yan Qin, Yao Li, Tienan Feng, Hui Pan, Jiayong Li, Fang Zhang, Yong Liu, Jianxin Qiu, Bo Sun
Author Information
  1. Yan Qin: Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  2. Yao Li: Clinical Center for Intelligent Rehabilitation Research, Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai, China.
  3. Tienan Feng: Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  4. Hui Pan: Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  5. Jiayong Li: Laboratory Medical Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  6. Fang Zhang: Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  7. Yong Liu: Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  8. Jianxin Qiu: Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  9. Bo Sun: Shanghai Center for Drug Evaluation and Inspection, Shanghai, China.

Abstract

Background: tacrolimus is one of the most commonly used basic immunosuppressants nowadays, but the high variability of tacrolimus blood concentration often leads to kidney transplant recipients frequently experiencing drug concentrations above or below the target concentration, resulting in renal toxicity or rejection of the transplanted kidney. The aim of this study is to explore the correlation of renal function with intra-patient variability (IPV) of tacrolimus blood concentration among recipients of renal transplants at 1-, 3-, 5-, and 10-year post-transplantation.
Methods: Recipients of renal transplants who were treated with tacrolimus for immunosuppression at the Shanghai General Hospital between January 2001 and December 2009, and followed up until 2019 were included in this retrospective study. Demographic characteristics and laboratory investigation results at their 1-, 3-, 5-, and 10-year follow-up visits were collected from their hospital medical records. patients were divided into a low or high IPV group based on the IPV of their tacrolimus concentrations.
Results: A total of 167 kidney transplant recipients were included in the study. At the 3-year follow-up visit, patients in the low IPV group had significantly lower blood urea nitrogen (BUN) (6.3��1.8 . 8.2��6.2 ��mol/L, P=0.04), serum creatinine (Scr) (88.8��23.6 . 104.8��39.6 ��mol/L, P=0.009), and blood uric acid (UA) (329.1��80.2 . 375.9��95.1 ��mol/L, P=0.004), as well as significantly higher estimated glomerular filtration rate (eGFR) values than patients in the high IPV group. Blood UA levels were significantly lower in patients in the low IPV group than the high IPV group at the 10-year follow-up (362.7��92.6 . 398.5��105.2 ��mol/L, P=0.042). There was no significant difference between the low and high IPV groups with respect to BUN, Scr, UA, or eGFR at the 1- and 5-year follow-up.
Conclusions: Recipients of renal transplants with lower IPV in tacrolimus concentration appeared to have better renal function over time. Controlling IPV may contribute to improved renal outcomes post-transplantation.

Keywords

References

  1. Sci Rep. 2023 Oct 2;13(1):16502 [PMID: 37783764]
  2. Front Transplant. 2024 Sep 25;3:1405070 [PMID: 39386200]
  3. Adv Chronic Kidney Dis. 2020 Jan;27(1):56-66 [PMID: 32147003]
  4. Exp Clin Transplant. 2012 Jun;10(3):239-42 [PMID: 22631059]
  5. Pediatr Transplant. 2022 Sep;26(6):e14297 [PMID: 35466485]
  6. Transplant Proc. 2019 Jul - Aug;51(6):1754-1757 [PMID: 31255354]
  7. Pharmacogenomics. 2017 Nov;18(16):1503-1513 [PMID: 28952408]
  8. Clin J Am Soc Nephrol. 2021 Nov;16(11):1723-1729 [PMID: 33820759]
  9. Expert Rev Clin Pharmacol. 2024 May-Jun;17(5-6):505-514 [PMID: 38725273]
  10. Expert Rev Clin Immunol. 2019 Dec;15(12):1323-1331 [PMID: 31721605]
  11. Urol Int. 2014;92(3):328-33 [PMID: 24480999]
  12. Transpl Int. 2024 Apr 17;37:12591 [PMID: 38694489]
  13. Clin Transl Sci. 2022 Jun;15(6):1544-1555 [PMID: 35373449]
  14. PLoS One. 2018 May 10;13(5):e0196552 [PMID: 29746495]
  15. Int J Mol Sci. 2022 Nov 30;23(23): [PMID: 36499372]
  16. Asian Biomed (Res Rev News). 2024 Jun 28;18(3):92-108 [PMID: 39175954]
  17. Pharmgenomics Pers Med. 2018 Mar 07;11:23-33 [PMID: 29563827]
  18. Nephrol Dial Transplant. 2010 Aug;25(8):2757-63 [PMID: 20190242]
  19. Sci Rep. 2022 Sep 28;12(1):16169 [PMID: 36171260]
  20. Am J Transplant. 2019 Oct;19(10):2805-2813 [PMID: 30859672]
  21. Curr Drug Metab. 2018;19(6):513-522 [PMID: 29380698]
  22. Ther Drug Monit. 2024 Aug 1;46(4):456-459 [PMID: 38648652]
  23. Front Immunol. 2021 Sep 30;12:746013 [PMID: 34659243]

Word Cloud

Created with Highcharts 10.0.0IPVrenaltacrolimushighconcentrationstudygroupvariabilitybloodkidneyrecipientsfunction10-yearfollow-uplow6��mol/LP=0transplants1-patientssignificantlylower2UAtransplantconcentrationsintra-patientamong3-5-post-transplantationRecipientsincludedretrospectiveBUN8ScreGFRBackground:TacrolimusonecommonlyusedbasicimmunosuppressantsnowadaysoftenleadsfrequentlyexperiencingdrugtargetresultingtoxicityrejectiontransplantedaimexplorecorrelationMethods:treatedimmunosuppressionShanghaiGeneralHospitalJanuary2001December2009followed2019DemographiccharacteristicslaboratoryinvestigationresultsvisitscollectedhospitalmedicalrecordsPatientsdividedbasedResults:total1673-yearvisitureanitrogen3��12��604serumcreatinine888��231048��39009uricacid3291��803759��951004wellhigherestimatedglomerularfiltrationratevaluesBloodlevels3627��923985��105042significantdifferencegroupsrespect5-yearConclusions:appearedbettertimeControllingmaycontributeimprovedoutcomesCorrelationtransplants:Intra-patienttransplantation

Similar Articles

Cited By

No available data.